pharma · Becker Muscular Dystrophy · Muscular Dystrophies · EWTX
Edgewise Therapeutics
NovaPharmaNews editorial coverage mentioning Edgewise Therapeutics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 1715 38th St., Boulder, CO 80301, US
- Founded
- 2017
- Employees
- 154
- Programs
- 15
- Drugs
- 3
- Patents
- 7
News & analysis
NovaPharmaNews articles mentioning Edgewise Therapeutics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Edgewise Therapeutics — regulatory, clinical, and market analysis.
Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test
Edgewise Therapeutics says EDG-7500 met a key Phase 2 test in obstructive hypertrophic cardiomyopathy. The evidence points to a cardiac sarcomere modulator still in clinical development, with CIRRUS-HCM as the named study.
Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal
French pharmaceutical giant Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for an upfront payment of $1.55 billion, with potential milestone payments reaching up to $2.7 billion. This strategic move significantly expands Servier's footprint in the rare disease and neurology space.